Phathom Pharmaceuticals, Inc. announced that Terrie Curran will be appointed Chief Executive Officer effective upon the closing of the acquisition of Celgene Corporation by Bristol-Myers Squibb Company. She has also been appointed to Phathom's Board of Directors. Ms. Curran will succeed David Socks as part of a planned transition.

Mr. Socks will continue to serve as Chief Executive Officer until Ms. Curran joins and will then serve as interim Chief Financial Officer and continue to serve as a member of the Board. Phathom also announced the appointments of Michael Cola, Heidi Kunz, and Chris Slavinsky as members of the Board. Ms. Curran has more than 20 years of experience in the biopharmaceutical industry.

She has served as President, Global Inflammation and Immunology (I&I) Franchise and as a member of the Executive Committee at Celgene Corporation since 2017. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful launch of OTEZLA®. Mr. Slavinsky serves as Vice President, Takeda Center for External Innovation and Head, Gastroenterology Business Development, Externalization and Special Projects.

Previously, Chris served in a number of capacities at Pfizer, including as Chief Counsel of several Pfizer business segments.